News of the index components OMX Nordic 40

Index

OMXN40

SE0001809476

Real-time Nasdaq Stockholm 07:58:36 15/05/2026 pm IST			5-day change	1st Jan Change
2,604.00 ^PTS	-0.47%		-0.33%	+3.54%

07/05	Nordic stocks in North America - Autoliv fell 0.6 percent	FW
05/05	Nordic stocks in North America - Ericsson fell 0.7 percent	FW

News of the index components

03:32pm	BNP Paribas raises DSV price target to DKK 2,100 (2,000), reiterates Outperform - BN	FW
03:06pm	Di: Five stocks to buy – and three to sell following the earnings deluge	FW
01:02pm	No public short sellers remain in Saab	FW
12:57pm	Essity General Counsel buys shares worth SEK 1.3 million	FW
12:52pm	Boliden faces public short seller	FW
12:49pm	Marshall Wace no longer a public short seller in Evolution	FW
11:57am	Deutsche Bank raises Nokia price target to 13.5 euros (8.5), reiterates Buy	FW
11:18am	Nordea raises Alfa Laval price target to SEK 585 (575), reiterates Buy	FW
10:52am	UPM acquires Ray Technology patents from Avantium	FW
10:13am	Saab deepens naval cooperation with Poland's PGZ	FW
09:46am	Citigroup cuts Coloplast price target to DKK 425 (473), reiterates Neutral - BN	FW
09:41am	Morgan Stanley upgrades Ørsted to Overweight (Equal-weight), raises price target to DKK 225 (160) - BN	FW
09:37am	Goldman Sachs upgrades Epiroc to Buy (Neutral), price target raised to SEK 315 (230) - BN	FW
09:37am	BNP Paribas resumes coverage of Evolution with Outperform rating and SEK 740 price target - BN	FW
15/05	Vestas says Capital Group Companies increases holding to 5.04% in Vestas as of May 8, 2026	RE
15/05	AstraZeneca bladder cancer trial yields encouraging results	AN
14/05	Morgan Stanley Upgrades Ørsted to Overweight Rating, Boosts PT	MT
14/05	Goldman Sachs Upgrades Epiroc to Buy, Boosts PT	MT
14/05	AstraZeneca immunotherapy for stomach cancer green lit for NHS use	AN
14/05	Bernstein: Coloplast's FY26 Outlook Cut to Mitigate Near-term Risks; Price Target Down	MT
14/05	AstraZeneca's bladder cancer drug yields encouraging test results	AN
14/05	AstraZeneca Says Bladder Cancer Treatment Improves Survival Rates in Phase 3 Trial	MT
14/05	AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial	RE
14/05	AstraZeneca says no new safety signals for Imfinzi with or without Imjudo plus Enfortumab Vedotin	RE
14/05	AstraZeneca Combo Therapy Shows Improved Event-free, Overall Survival in Bladder Cancer	MT
14/05	Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring	RE
13/05	Saab, PGZ group establish naval domain collaboration	RE
13/05	Kepler Cheuvreux Upgrades Novonesis to Buy, Boosts PT	MT
13/05	AlphaValue/Baader Europe Upgrades Sandvik to Add, Trims PT	MT
13/05	AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making	MT
13/05	Novo Nordisk Canada and Rexall Pharmacy partner to offer convenience, support, and home delivery for Canadians taking Ozempic and Wegovy	RE
13/05	Ireland's 2 Billion Euros Tap of October 2043 Green Bond Draws Strong Demand	DJ
13/05	Astrazeneca Expands AI Partnership With Owkin Under Three-Year Licensing Deal	MT
13/05	Novo Nordisk Says Wegovy Pill Delivered Substantial Weight Loss, Mobility Improvement in Phase 3 Trial Analyses	MT
13/05	Novo Nordisk Pauses Manufacturing Plans at Odense Site, Layoff 150 Workers	MT
13/05	Denmark's Novo Nordisk Halts Development of Manufacturing Facility in Odense	MT
13/05	Sterling edges lower as Starmer pressure keeps markets cautious	RE
13/05	Novo Nordisk halts Odense construction and issues layoff notices	FW
13/05	DSV, Volvo Autonomous Solutions launch operations in Texas, U.S.	RE
13/05	Essity Board Member Buys SEK 29.6 Mln Worth Of Essity Shares	RE